ArticleJournal of gynecologic oncology2025

A phase II study of induction PD-1 blockade (nivolumab) in patients with surgically completely resectable mismatch repair deficient endometrial cancer (NIVEC).

Yong Jae Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.